↓ Skip to main content

A randomized, double-blind, phase 2b proof-of-concept clinical trial in early Alzheimer’s disease with lecanemab, an anti-Aβ protofibril antibody

Overview of attention for article published in Alzheimer's Research & Therapy, April 2021
Altmetric Badge

About this Attention Score

  • In the top 5% of all research outputs scored by Altmetric
  • One of the highest-scoring outputs from this source (#3 of 1,248)
  • High Attention Score compared to outputs of the same age (99th percentile)
  • High Attention Score compared to outputs of the same age and source (98th percentile)

Mentioned by

news
118 news outlets
blogs
3 blogs
twitter
70 tweeters
facebook
1 Facebook page

Citations

dimensions_citation
182 Dimensions

Readers on

mendeley
202 Mendeley
You are seeing a free-to-access but limited selection of the activity Altmetric has collected about this research output. Click here to find out more.
Title
A randomized, double-blind, phase 2b proof-of-concept clinical trial in early Alzheimer’s disease with lecanemab, an anti-Aβ protofibril antibody
Published in
Alzheimer's Research & Therapy, April 2021
DOI 10.1186/s13195-021-00813-8
Pubmed ID
Authors

Chad J. Swanson, Yong Zhang, Shobha Dhadda, Jinping Wang, June Kaplow, Robert Y. K. Lai, Lars Lannfelt, Heather Bradley, Martin Rabe, Akihiko Koyama, Larisa Reyderman, Donald A. Berry, Scott Berry, Robert Gordon, Lynn D. Kramer, Jeffrey L. Cummings

Twitter Demographics

The data shown below were collected from the profiles of 70 tweeters who shared this research output. Click here to find out more about how the information was compiled.

Mendeley readers

The data shown below were compiled from readership statistics for 202 Mendeley readers of this research output. Click here to see the associated Mendeley record.

Geographical breakdown

Country Count As %
Unknown 202 100%

Demographic breakdown

Readers by professional status Count As %
Researcher 27 13%
Other 20 10%
Student > Ph. D. Student 16 8%
Student > Bachelor 14 7%
Student > Postgraduate 8 4%
Other 29 14%
Unknown 88 44%
Readers by discipline Count As %
Medicine and Dentistry 28 14%
Neuroscience 27 13%
Pharmacology, Toxicology and Pharmaceutical Science 11 5%
Biochemistry, Genetics and Molecular Biology 9 4%
Agricultural and Biological Sciences 8 4%
Other 22 11%
Unknown 97 48%

Attention Score in Context

This research output has an Altmetric Attention Score of 918. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 27 January 2023.
All research outputs
#15,330
of 23,049,027 outputs
Outputs from Alzheimer's Research & Therapy
#3
of 1,248 outputs
Outputs of similar age
#664
of 432,428 outputs
Outputs of similar age from Alzheimer's Research & Therapy
#1
of 54 outputs
Altmetric has tracked 23,049,027 research outputs across all sources so far. Compared to these this one has done particularly well and is in the 99th percentile: it's in the top 5% of all research outputs ever tracked by Altmetric.
So far Altmetric has tracked 1,248 research outputs from this source. They typically receive a lot more attention than average, with a mean Attention Score of 25.9. This one has done particularly well, scoring higher than 99% of its peers.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 432,428 tracked outputs that were published within six weeks on either side of this one in any source. This one has done particularly well, scoring higher than 99% of its contemporaries.
We're also able to compare this research output to 54 others from the same source and published within six weeks on either side of this one. This one has done particularly well, scoring higher than 98% of its contemporaries.